
Coala Life - Positive progress, but financial challenges remain

Redeye provides an update following the Q1'23 report from Coala Life. Although the 18% q/q reduction in OPEX and 30% q/q sales growth are encouraging, they slightly miss our expectations. However, we find reassurance in the company's decision to pursue factoring to finance the rapidly accumulating account receivables, which has been straining its working capital. Additionally, the average revenue per patient /month trended upward, reaching USD85 in Q4'22 and cUSD105 in Q1'23. We have made minor adjustments to our near-term estimates. Yet, our fair value range remains unchanged, with a base case of SEK1.3 per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Coala Life - Positive progress, but financial challenges remain](#)